Comparison of immunogenicity of two hepatitis A vaccines — VAQTA® and HAVRIX® — in young adults

Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS®) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio®) given as a booster dose at 6 years of age

“…13 Based on observed and predicted long-term persistence of vaccine-induced antibodies, similar conclusions have been reached from studies undertaken with other vaccines. [14][15][16][17][18][19][20][21][22][23] These data confirm the hypothesis that the half-life of antibody levels is a function of time: it is short after the initial vaccination and increases with subsequent booster doses.…”

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

“…These integrated safety results, in toddlers, are consistent with individual trial results in the same age group as well as with the safety data collected from other clinical trials and post-licensure studies over the last two decades. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] HAVi has been shown to be generally well-tolerated in a number of clinical trials with the majority of reported AEs being mild and consisting of either injection-site related events (e.g. erythema, swelling, pain, tenderness) or systemic but not serious events (e.g.…”

“…fever, irritability, diarrhea, vomiting, nausea, and headache). [3][4][5][6][7][8][9][10][11][12][13][14][15][16] These integrated immunogenicity analyses also showed that HAVi protective antibody concentrations were elicited in 100% of participants after two doses and 92% after a single dose regardless of whether HAVi was given concomitantly or not. These analyses also showed that HAVi does not affect the safety and immunogenicity profile of other vaccines, when given concomitantly.…”

“…2 Clinical trials conducted worldwide have demonstrated that HAVi vaccine is efficacious, immunogenic, and well-tolerated. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] In the US, hepatitis A was the most frequently reported type of hepatitis during the 1980s and 1990s, with an average of 26,000 cases reported per year. 17 However, the actual number of infections is known to have been several times higher, estimated at 270,000 annually, after correction of underreporting and asymptomatic disease.…”

Prevention of viral hepatitis

“…The vaccines are highly stable, have similar immunogenicity as reflected in humoral response [10], and probably have similar effectiveness. The circulating anti-HAV level following the two-dose vaccine schedule approaches that seen in natural infection and is 100-to 300-fold higher than that seen after Ig administration.…”